Los Angeles, CA – According to filings with the U.S. Securities and Exchange Commission, Respira Technologies is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Quigley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Respira Technologies
Respira Technologies, Inc. is a platform biotechnology company with a focus on aerosol science. We are focused on creating breakthrough aerosol devices and formulations that safely deliver a broad range of pharmaceuticals. It is our mission to protect public health through novel innovation, responsible sourcing, draft legislative proposals, transparent product information and common sense oversight. Respira is based in Los Angeles, CA and was founded by CEO Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies. The RespiRx is the first orientation-agnostic, portable VMN device that effectively operates in any position held by the patient. Respira sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs with safe and effective inhalable drug delivery mechanisms that only the RespiRx can deliver. Respira is backed by venture firms: Blue Ledge Capital, Compass Rose Asset Management, DG Ventures, Evolution VC Partners and Poseidon Asset Management.

To learn more about Respira Technologies, visit http://respiratechnologies.com/

Contact:
Brian Quigley, Chief Executive Officer
973-865-9982

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved